Janssen, P
#Alzheimers #Neurodegeneration #GLP1 #GLP1RA #Neuroscience #BrainHealth #DrugRepurposing #Biotech #Pharma #ClinicalTrials #AgingResearch #Dementia #LifeSciences #Neuroinflammation #HealthcareInnovation Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders - Nature Aging nature.com This feels similar to other disease areas where intervention timing made all the difference
Its built on understanding your habits, developing long-term skills, and making choices you can actually stick with
Cui H, Yang H, Abdel-Samie MA, Siva S, Lin L
In front of such a wide range of options, as well as of the unmet need for every obese patient, the task to accomplish remains finding out the optimal individually tailored therapeutic regimen to treat obesity
Dispensation of 3.0-mg dulaglutide at index was less common for both cohorts, with only 1.4% in cohort 1 and 0.5% in cohort 2